These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26900611)

  • 1. Supreme Court rules against Teva in Copaxone® patent fight.
    Sklan A
    Pharm Pat Anal; 2014 Jul; 3(4):350-1. PubMed ID: 26900611
    [No Abstract]   [Full Text] [Related]  

  • 2. Teva Pharmaceuticals v. Sandoz: availability of generic glatiramer acetate and the impact to patent litigation claim construction.
    Fogel LE; Ray CJ
    Expert Opin Ther Pat; 2015 Jan; 25(1):1-4. PubMed ID: 25363310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supreme Court to decide whether payments by patent holders to delay production of generics are anticompetitive.
    Roehr B
    BMJ; 2012 Dec; 345():e8464. PubMed ID: 23236054
    [No Abstract]   [Full Text] [Related]  

  • 4. Generics still unable to resolve ANDA patent issues by declaratory judgment, but is a supreme court resolution on the way?
    Eccleston LE
    Health Care Law Mon; 2006 Dec; ():3-5. PubMed ID: 17236678
    [No Abstract]   [Full Text] [Related]  

  • 5. On access and accountability--two Supreme Court rulings on generic drugs.
    Boumil MM; Curfman GD
    N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
    [No Abstract]   [Full Text] [Related]  

  • 6. Sublicense or supply agreement? Supreme Court of Canada interpretation benefits generic pharmaceutical industry.
    Burshtein S
    Food Drug Law J; 1999; 54(1):73-91. PubMed ID: 11758562
    [No Abstract]   [Full Text] [Related]  

  • 7. Supreme Court rules against drug patent "evergreening".
    Kondro W
    CMAJ; 2006 Dec; 175(12):1508-9. PubMed ID: 17146081
    [No Abstract]   [Full Text] [Related]  

  • 8. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry.
    Ritter M; Tempesta J; Ragusa P
    Pharm Pat Anal; 2014 Jul; 3(4):345-7. PubMed ID: 25291307
    [No Abstract]   [Full Text] [Related]  

  • 9. Canadian court upholds Glaxo's patent on AZT.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2001; 6(1-2):53-7. PubMed ID: 11837029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patent infringement. Generic HIV drugmaker's patent claim is time-barred.
    AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916
    [No Abstract]   [Full Text] [Related]  

  • 11. Intellectual property. Drug patents at the Supreme Court.
    Hemphill CS; Sampat B
    Science; 2013 Mar; 339(6126):1386-7. PubMed ID: 23520096
    [No Abstract]   [Full Text] [Related]  

  • 12. High Court strikes down Merck's patent on alendronate.
    Dyer O
    BMJ; 2003 Feb; 326(7383):243. PubMed ID: 12560269
    [No Abstract]   [Full Text] [Related]  

  • 13. Patent watch.
    Harrison C
    Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274462
    [No Abstract]   [Full Text] [Related]  

  • 14. How Patent Troll Legislation Can Increase Timely Access to Generic Drugs.
    Treasure CL; Kesselheim AS
    JAMA Intern Med; 2016 Jun; 176(6):729-30. PubMed ID: 27183456
    [No Abstract]   [Full Text] [Related]  

  • 15. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 16. Three years on from Teva, where are we now?
    Adamo KR; Goryunov E; Hubbard RM; Craig SM
    Pharm Pat Anal; 2018 Sep; 7(5):175-177. PubMed ID: 30066608
    [No Abstract]   [Full Text] [Related]  

  • 17. Muddying the waters: how the Supreme Court's decision in Merck v. Integra fails to resolve problems of judicial interpretation of 35 U.S.C. Section 271(E)(1), the "safe harbor" provision of the Hatch-Waxman Act.
    Sertic M
    Health Matrix Clevel; 2007; 17(2):377-439. PubMed ID: 18326397
    [No Abstract]   [Full Text] [Related]  

  • 18. Pfizer receives US$2.15 billion in patent damages.
    Sklan A
    Pharm Pat Anal; 2013 Sep; 2(5):583. PubMed ID: 24386655
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug patent protection: how long is long enough?
    Sibbald B
    CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
    [No Abstract]   [Full Text] [Related]  

  • 20. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.